140 related articles for article (PubMed ID: 36734062)
1. Intravaginal delivery for CRISPR-Cas9 technology: For example, the treatment of HPV infection.
Zhen S; Chen H; Lu J; Yang X; Tuo X; Chang S; Tian Y; Li X
J Med Virol; 2023 Feb; 95(2):e28552. PubMed ID: 36734062
[TBL] [Abstract][Full Text] [Related]
2. Vaginal siRNA delivery: overview on novel delivery approaches.
Baxi K; Sawarkar S; Momin M; Patel V; Fernandes T
Drug Deliv Transl Res; 2020 Aug; 10(4):962-974. PubMed ID: 32170657
[TBL] [Abstract][Full Text] [Related]
3. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
[TBL] [Abstract][Full Text] [Related]
4. New approaches to moderate CRISPR-Cas9 activity: Addressing issues of cellular uptake and endosomal escape.
van Hees M; Slott S; Hansen AH; Kim HS; Ji HP; Astakhova K
Mol Ther; 2022 Jan; 30(1):32-46. PubMed ID: 34091053
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
6. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
8. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
9. Liposomal delivery of CRISPR/Cas9.
Zhen S; Li X
Cancer Gene Ther; 2020 Aug; 27(7-8):515-527. PubMed ID: 31676843
[TBL] [Abstract][Full Text] [Related]
10. A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Verma R; Sahu R; Singh DD; Egbo TE
Semin Cell Dev Biol; 2019 Dec; 96():44-52. PubMed ID: 30986568
[TBL] [Abstract][Full Text] [Related]
11. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
12. An effective vaginal gel to deliver CRISPR/Cas9 system encapsulated in poly (β-amino ester) nanoparticles for vaginal gene therapy.
Niu G; Jin Z; Zhang C; He D; Gao X; Zou C; Zhang W; Ding J; Das BC; Severinov K; Hitzeroth II; Debata PR; Ma X; Tian X; Gao Q; Wu J; You Z; Tian R; Cui Z; Fan W; Xie W; Huang Z; Cao C; Xu W; Xie H; Xu H; Tang X; Wang Y; Yu Z; Han H; Tan S; Chen S; Hu Z
EBioMedicine; 2020 Aug; 58():102897. PubMed ID: 32711250
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes.
Zhen S; Liu Y; Lu J; Tuo X; Yang X; Chen H; Chen W; Li X
Hum Gene Ther; 2020 Mar; 31(5-6):309-324. PubMed ID: 31973584
[TBL] [Abstract][Full Text] [Related]
14. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
Xu Y; Liu R; Dai Z
Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
[TBL] [Abstract][Full Text] [Related]
15. Synthetic nanoparticles for the delivery of CRISPR/Cas9 gene editing system: classification and biomedical applications.
Zheng Q; Wang W; Zhou Y; Mo J; Chang X; Zha Z; Zha L
Biomater Sci; 2023 Aug; 11(16):5361-5389. PubMed ID: 37381725
[TBL] [Abstract][Full Text] [Related]
16. Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.
Zhang BC; Luo BY; Zou JJ; Wu PY; Jiang JL; Le JQ; Zhao RR; Chen L; Shao JW
ACS Appl Mater Interfaces; 2020 Dec; 12(51):57362-57372. PubMed ID: 33301289
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
18. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
[TBL] [Abstract][Full Text] [Related]
19. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]